RE:RE:RE:RE:RE:RE:RE:RE:RE:rbc update wow scripts... all up againThere definitely were those two examples you have given in the past, but that is a far cry from 2,500% and 2,700%.
LaticelnExile wrote: Yes! Of course! My data is the same as Billy Kenber' s data that is publically available - if youhave the time and inclination to go through the nhs tariff books. I have noted AMCo price increases ranging from 500% to 1400% on select drugs in my previous posts. Good luck to all.
Lumberfeverlong wrote: There are a bunch of "in the event", "could" and "believe" qualifiers in the passage. Moreover, the inestigation with Flynn and Pfizer appears to relate to increasing prices by 25 to 27 times historical levels. I am not aware of any drug in the Concordia portfolio that comes close to that. Do you Lattice?
LaticelnExile wrote: patenright11 wrote: FLYN AND PFIZER, THAT IS NOT CONCORDIA LETTUCE PHUC HEAD.
HERE YOU GO .... This explains the relevancy, from the RBC Report to Investors. Decision has not been made yet by the CMA. Doesn't look good tho', IMO
Key points:
Outcome of Flynn Pharma/Pfizer Competition and Marketing Authority (CMA) investigation potentially relevant to AMCo pricing behaviour.
Flynn and Pfizer are alleged to have sold an epilepsy drug, phenytoin sodium, with little competition, to the NHS for 25-27 times higher than historical prices. In the event that the CMA determines Pfizer/ Flynn's behaviour impaired genuine competition and drug pricing was excessive and unfair and fines the companies etc..., we believe attention could turn to other companies which have significantly increased the prices of certain drugs, including Concordia, and this could place an additional overhang on the shares if the outcome were negative.